Search results
Pfizer’s gene-therapy trial failure boosts Sarepta’s stock
Market Watch· 3 days agogained 4% premarket on Thursday after a potential competitor to its gene therapy stumbled in a...
Is this the Time to Initiate a Pfizer (PFE) Position?
Insider Monkey via Yahoo Finance· 5 days agoDiamond Hill Capital, an investment management company, released its “Select Strategy” first-quarter...
Pfizer (PFE) Stock Declines While Market Improves: Some Information for Investors
Zacks via Yahoo Finance· 4 days agoPfizer (PFE) closed the latest trading day at $27.66, indicating a -1.32% change from the previous...
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It
Zacks· 7 days agoFree Report) has recently been on Zacks.com's list of the most searched stocks. During this period, the Zacks Large Cap Pharmaceuticals industry, which Pfizer falls in, has ...
Pfizer Inc. (NYSE:PFE) Shares Sold by Public Employees Retirement System of Ohio
ETF DAILY NEWS· 3 days agoPublic Employees Retirement System of Ohio reduced its stake in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 1.8% during the 4th quarter, HoldingsChannel reports. The ...
Pfizer Inc. (NYSE:PFE) Shares Sold by Waddell & Associates LLC
ETF DAILY NEWS· 6 days agoWaddell & Associates LLC reduced its position in Pfizer Inc. (NYSE:PFE – Free Report) by 40.0% in the 4th quarter, according to its most recent disclosure with the Securities ...
Pfizer's Duchenne gene therapy fails in late-stage study
Reuters via AOL· 4 days agoThe therapy also did not show a significant difference compared to placebo in secondary goals of the...
Studio Investment Management LLC Buys 2,236 Shares of Pfizer Inc. (NYSE:PFE)
ETF DAILY NEWS· 2 days agoStudio Investment Management LLC increased its stake in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 2.1% during the 4th quarter, according to the company in its most ...
Pfizer Provides Update on Phase 3 Study of Investigational Gene Therapy for Ambulatory Boys with...
Morningstar· 4 days agoPfizer Inc. (NYSE: PFE) today announced that CIFFREO, a Phase 3 global, multicenter, randomized, double-blind, placebo-controlled study evaluating the investigational mini-dystrophin ...
Pfizer Inc. (NYSE:PFE) Shares Sold by Cresset Asset Management LLC
ETF DAILY NEWS· 5 days agoCresset Asset Management LLC reduced its stake in Pfizer Inc. (NYSE:PFE – Free Report) by 13.5% in the fourth quarter, according to the company in its most recent disclosure ...